SEARCH

SEARCH BY CITATION

References

  • 1
    Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997; 63: 331338.
  • 2
    Kasiske BL. Epidemiology of cardiovascular disease after renal transplantation. Transplantation 2001; 72: 5558.
  • 3
    Massey ZA. Hyperlipidemia and cardiovascular disease after organ transplantation. Transplantation 2001; 72: S13S15.
  • 4
    First MR. Strategies to minimize immunological and nonimmunological risk factors in the renal transplant population. Transplantation 2001; 72: S20S24.
  • 5
    United States Renal Data System. USRDS 1995 annual data report. Bethesda , MD : NIH, NIDDK, 1995.
  • 6
    Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002; 2: 807818.
  • 7
    Massy ZA, Kasiske BL. Post-transplant hyperlipidemia: Mechanisms and management. J Am Soc Nephrol 1996; 7: 971977.
  • 8
    Miller LW, Schlant RC, Kobashigawa J, Kubo S, Renlund DG. 24th Bethesda Conference: Heart transplantation. Task force 5: Complications. J Am Coll Cardiol 1993; 22: 4154.
  • 9
    Blum A, Aravot D. Heart transplantation—an update. Clin Cardiol 1996; 19: 930938.
  • 10
    Ong CS, Pollock CA, Caterson RJ, Mahony JF, Waugh DA, Ibels LS. Hyperlipidemia in renal transplant recipients: Natural history and response to treatment. Medicine 1994; 73: 215223.
  • 11
    Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The registry of the international society for heart and lung transplantation: Seventeenth official report–2000. J Heart Lung Transplant 2000; 19: 909931.
  • 12
    Kirk JK, Dupuis RE. Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient. Ann Pharmacother 1995; 29: 879891.
  • 13
    Zetia® Product Information. Merck/Schering-Plough Pharmaceuticals 2001, 2002. Knopp RH. Drug treatment of lipid disorders. N Eng J Med 1999; 341: 498511.
  • 14
    Davignon J, Montigny M, Dufour R. HMG-CoA reductase inhibitors: A look back and a look ahead. Can J Cardiol 1992; 8: 843864.
  • 15
    Kosglou T, Meyer I, Veltri EP et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002; 54: 309319.
  • 16
    Knopp RH. Drug treatment of lipid disorders. N Eng J Med 1999; 341: 498511.
  • 17
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 24862497.
  • 18
    National Kidney Foundation. Kidney Disease Outcomes Quality Initiative (NKF K/DOQI) Clinical Practice Guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 2003; 41(suppl 3): S1S91.
  • 19
    Sudhop T, Lutjohann D, Kodel A et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106: 19431948.
  • 20
    Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe co-administered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002; 105: 24692475.